Researchers at NYU Langone Health and Janssen Biotech Inc. have reported on mAbtyrins, bioengineered molecules composed of human monoclonal antibodies and centyrins that are a new way to fight Staphylococcus aureus infection on all fronts.In their experiments, which were published in Cell Host & Microbe on April 24, 2023, the team described mAbtyrin, as “a protein-based therapeutic that targets 10 disease-causing mechanisms employed by S. aureus,” senior author Victor Torres told BioWorld. Read More
A unique characteristic of Helicobacter pylori could serve to end infections of this gastric bacterium. A group of scientists from the University of Munich have found that this pathogen has a strategic point in its mitochondrial respiratory complex I that could be targeted with inhibitors. “We did not look for respiration inhibitors in the first place,” co-senior author Wolfgang Fischer told BioWorld. “We screened libraries with a reporter assay, looking for something different, a particular protein secretion, the secretion system type (T4SS). Then, we found that a lot of compounds inhibit this process. From these compounds, we came to the point that they are actually respiration inhibitors,” he explained. Read More
Turbinmicin analogues reported to be useful for the treatment of fungal infections have been described in a recent Wisconsin Alumni Research Foundation (WARF) patent. Read More
A Blacksmith Medicines Inc. patent describes the development of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of complicated urinary tract infections (UTIs). Read More
Stoke Therapeutics Inc. has received clinical trial application (CTA) clearance from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study (OSPREY) of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA). Read More
Research at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the development of proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker. Read More
Son of sevenless homolog 1 (SOS1) inhibitors have been detailed in a Shanghai Allist Pharmaceuticals Co. Ltd. patent and described as useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome (neurofibromatosis type 1-like syndrome), neurofibromatosis type 1, Noonan syndrome and Splenomegaly, among others. Read More
Researchers from Arvinas Inc. and affiliated organizations presented the discovery and preclinical evaluation of ARV-766, a novel androgen receptor (AR) degrading proteolysis targeting chimera (PROTAC), being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Read More
Claudin 18.2 (CLDN18.2) is involved in the formation of tight junctions and is expressed in normal gastric mucosa, maintaining its expression during malignant transformation of the gastric epithelium. It is also aberrantly expressed in other tumor types, such as esophageal, pancreatic and lung adenocarcinoma, making it an attractive target for cancer immunotherapy. Read More
Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease. Read More
Albatroz Therapeutics Pte Ltd. has secured $3 million in funding to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis. Read More
Cadherin 6 (CDH6) is a transmembrane protein with high expression during embryonic kidney development, with very limited expression in adult tissues but overexpressed in several malignancies such as ovarian or renal cancer, and it is tied disease progression and poor prognosis. This pattern of expression makes it an attractive target for antibody-drug conjugate (ADC) development. Read More
Additional early-stage research and drug discovery news in brief, from: Dyve Biosciences, Eyevensys, Palatin Technologies, Sernova, Valitor, Zyversa Therapeutics. Read More